Aleph Blog

 Subscribe in a reader

Disclosure

This blog is produced by David Merkel CFA, a registered representative of Finacorp Securities as an outside business activity. As such, Finacorp Securities does not review or approve materials presented herein. By viewing or participating in discussion on this blog, you understand that the opinions expressed within do not reflect the opinions or recommendations of Finacorp Securities, but are the opinions of the author and individual participants. Neither the information nor any opinion expressed constitutes a solicitation for the purchase or sale of any security or other instrument. Before investing, consider your investment objectives, risks, charges and expenses. Any purchase or sale activity in any securities instrument should be based upon your own analysis and conclusions. Past performance is not indicative of future results. Finacorp Securities is a member FINRA and SIPC.

David Merkel

At my blog there are two main purposes: teaching investors about better investing through risk control, and tying all of the markets into a coherent whole.

Latest



Archives


Categories


  • Recent Comments:

    • Guillermo Roditi: OK, so am I the only one that thinks transaction taxes are ridiculous? It seems to me like they...
    • brad greenspan: very well put, david
    • najdorf: This is perhaps more of a comment on your #3, but large corporations imitate governments in this respect...
    • najdorf: Another (utterly non-mathematical) way to look at risk management is on a relative scale. We don’t...
    • Lurker: It’s good to get technical every once in a while. It lets some of these other commenters know who...
  • Recent Trackbacks:

  •  Subscribe in a reader

     Subscribe in a reader (comments)

    Subscribe to RSS Feed

    Enter your Email


    Preview | Powered by FeedBlitz

    Seeking Alpha Certified

    Featured blogger at Wealth Managers League

    Top markets blogs award

    The Aleph Blog

    Top markets blogs

    InstantBull.com: Bull, Boards & Blogs

    Blog Directory - Blogged

    IStockAnalyst

    http://www.wikio.com

    Search

     

    Advertising


    blog advertising is good for you

    Books I Have Reviewed

    Book Reviews

    Other Advertising

    Portfolio Reshaping Mid-Year 2007, Part 3

    Time for my most recent portfolio changes. The reshaping is complete, here is the data file and here are the qualitative details:

    Buys

    1. Arkansas Best [ABFS] — Inexpensive, and trucking is out of favor. Trucking should pick up with the economy in the second half of 2007, and as the dollar cheapens, trucking is needed to get the exports to the ports.
    2. Deutsche Bank [DB] — Cheap major European bank. I’m light on financials (though if I lost my restrictions you would see a lot of insurance in my portfolio). 9-10x earnings for the next two years seems too cheap for me. Can they have that much exposure to the same problems faced by Bear Stearns? Maybe, but the valuation compensates for that.
    3. Gruma SA [GMK] — Inexpensive, and a play on the growing middle class in Mexico. Also a play on the growing popularity of Mexican food in the world. I don’t have a lot in consumer staples, so this helps.
    4. Mylan Labs [MYL] — returning to a name I last owned in 1988. Inexpensive generic drugmaker. I have nothing in healthcare, so this diversifies me a little. Generics are unlikely to fare badly as the branded pharmaceuticals should the Democrats win in 2008.

    Sales

    1. Sold Komag [KOMG] because of the merger, and the arb premium (amount of incremental gains from holding on until deal consummation) was less than what I could earn in cash.
    2. Sold St. Joe [JOE], and I wish I had sold when one of my colleagues explained their likely troubles to me one month ago. St. Joe is going to have it tough for a while because they don’t have a lot of ways to generate cash, without selling property, and the land market is not as good as it was two years ago.
    3. Sold Sappi [SPP]. The glossy paper market, like other fiber markets faces their share of challenges. Demand is sluggish, and likely to stay that way for a while.
    4. Sold a little of Lafarge [LR]. Still have a position there. It’s had a nice run, so I rebalanced down to my normal target weight.

    With these moves, I am back to 35 positions, up from 34. I am running with 16% cash, which is high for me. At the beginning of the year, I reinvested and brought cash down to 5% of the portfolio, but good investment results, combined with rebalancing has brought the cash back, and then some. If the cash hits 20%, I will raise my normal portfolio position size, and move cash to 10% or so. Maybe we get a pullback?

    What I did not sell

    1. SPX Corp — the turnaround continues. For now, honor the momentum.
    2. Noble Corp — Hey, I just bought this last during the reshaping; I am not kicking it out so soon, no matter how well it has done.
    3. Sara Lee — the turnaround continues. No momentum here; maybe management will succeed. A few of their ideas seem to be on target.

    What I did not buy

    Many more entries here. As I worked down my list, I kept saying, “Cheap for a reason… cheap for a reason…”

    1. Too small: Charles and Colvard, PAM Transportation
    2. Don’t care for the industry: Chipmos Technologies, Finish Line, Foot Locker, Encore Wire, First Consulting, Freightcar America, Korea Electric, and Metrogas
    3. Already own something that I like better in its industry, and don’t want to increase exposure: Crystal River and MVC Capital (both interesting, though I like Deerfield better)
    4. Irregular operating history: Optimal Group and Northgate Minerals
    5. Tyco International is not as cheap as the data would indicate because of the recent spinoffs.

    After I finish this, I will adjust the portfolio over at Stockpickr.com.
    Full Disclosure: Long SPW NE SLE LR GMK DB ABFS MYL

    3 Responses to “ Portfolio Reshaping Mid-Year 2007, Part 3 ”

    1. Scott McCartney Says:

      David,

      Good luck with MYL. We owned at work just prior to the disastrous King deal, with ultimately scuttled, and we eventually sold at a 15% loss. We learned a few things that we should have caught prior to purchase: governance/CEO issues (listen to how Coury handles himself on calls), the business is a lousy one (the make all their money in a short time window when a drug first comes off patent), and “authorized” generics are a real challenge. As you can probably tell, I can’t stand the stock as it cost my clients money :-)

    2. amccabe Says:

      Speaking of the TYC split, did you look at the spinoffs TEL and COV? I’ve been looking to add some healthcare to diversify, also, so I bought some Covidien this week. It wasn’t easy tracking down fundamentals, but compared against JNJ it looks like it trades at a discount on P/S and P/B (probably justified to some extent), and has room for margin improvement.

    3. PaulinKansasCity Says:

      Thanks for this David; as always your insights are helpful.

    Leave a Reply